"Cardiotoxicity of Oncologic Treatments" ed. by Manuela Fiuza

Many drugs, including those used in cancer patient treatments can cause injuries to human heart. As number of cured cancer patients continues to increase, the issue of cardiotoxicity is currently being subject of intensive research, since it can harmly influence long-term health condition of patients. This book reviews this subject over seven chapters which are briefly described below.

Early detection of the patients proneness for developing cardiotoxicity is the key issue to decrease morbidity and mortality. It also facilitates more tailored therapeutic interventions. Therefore, the collaboration and interaction of cardiology and oncology may contribute to reducing the cardiovascular adverse effects and improving the results in the treatment of patients with cancer.

Contents
Preface
1 Cardiovascular Pathophysiology Produced by Natural Toxins and Their Possible Therapeutic Implications
2 Role of Nitric Oxide in Isoproterenol-Induced Myocardial Infarction
3 Cardiac Complications of Cancer Treatment
4 Neuregulinl-ErbB Signaling in Doxorubicin-Induced Cardiotoxicity
5 Doxorubicin-Induced Oxidative Injury of Cardiomyocytes - Do We Have Right Strategies for Prevention?
6 Trastuzumab and Cardiotoxicity
7 Early Detection and Prediction of Cardiotoxicity - Bio marker and Echocardiographic Evaluation